# MULTI-OMICS TEMPORAL PROFILING OF AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS AN ASSOCIATION OF THERAPEUTIC RESPONSE TO ADALIMUMAB WITH DISEASE ACTIVITY AND INNATE / ADAPTIVE IMMUNITY

- 4 Daniel Sobral<sup>1,2</sup>, Ana F Fernandes<sup>3</sup>, Atlas Sardoo<sup>4</sup>, Miguel Bernardes<sup>5,6</sup>, Patrícia Pinto<sup>7</sup>, Helena
- 5 Santos<sup>4,8</sup>, João Lagoas-Gomes<sup>9</sup>, José Tavares-Costa<sup>10</sup>, José AP Silva<sup>11,12</sup>, João M Dias<sup>4,13</sup>,
- 6 Alexandra Bernardo<sup>6</sup>, Jean-Charles Gaillard<sup>14</sup>, Jean Armengaud<sup>14</sup>, Vladimir Benes<sup>15</sup>, Lúcia
- 7 Domingues<sup>4,16</sup>, Nélia Gouveia<sup>4,17</sup>, Sara Maia<sup>4,17</sup>, Jaime C Branco<sup>4,18</sup>, Ana V Coelho<sup>3</sup>, Fernando
- 8 M Pimentel-Santos<sup>4,18,\*</sup>
- 9 <sup>1</sup> Associate Laboratory i4HB Institute for Health and Bioeconomy, NOVA School of Science
- 10 and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal
- 11 <sup>2</sup> UCIBIO Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of
- 12 Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal
- <sup>3</sup> Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av.
   da República, 2780-157 Oeiras, Portugal
- 15 <sup>4</sup> CEDOC, FCM|Nova Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal
- <sup>5</sup> Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal
- <sup>6</sup> Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal
- <sup>7</sup> Rheumatology Department, Hospital Centre of Vila nova de Gaia espinho, Vila nova de Gaia,
   Porto, Portugal
- 20 <sup>8</sup> Portuguese Institute of Rheumatology, Lisboa, Portugal
- <sup>9</sup> Rheumatology Department, Centro Hospitalar do Tâmega e Sousa, Hospital Padre Américo,
   Penafiel, Portugal
- 23 <sup>10</sup> Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal
- <sup>11</sup> i.CBR Institute for Clinical and Biomedical Research, Faculty of Medicine, University of
   Coimbra, Portugal.
- 26 <sup>12</sup> Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Portugal.
- 27 <sup>13</sup> Rheumatology Department, Centro Hospitalar Médio Tejo, Torres Novas, Portugal
- <sup>14</sup> Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la
   Santé (DMTS), SPI, 30200 Bagnols sur Cèze, France
- 30 <sup>15</sup> EMBL Genomics Core Facility, Meyerhofstr. 1, D-69117 Heidelberg

- 31 <sup>16</sup> Escola Superior de Saúde Instituto Politécnico de Setúbal, Setúbal, Portugal
- 32 <sup>17</sup> NOVA Clinical Research Unit of Universidade Nova de Lisboa, Lisboa, Portugal
- <sup>18</sup> Rheumatology Department, CHLO, Hospital de Egas Moniz, Lisboa, Portugal
- 34 \* Corresponding author: pimentel.santos@nms.unl.pt
- 35

#### 36 ABSTRACT

**Background**: Axial Spondyloarthritis can lead to significant disability and impairment in quality of life. TNF inhibitors are recommended to patients enduring active disease despite conventional treatment. Nonetheless, up to 40% of patients of patients fail to respond to TNF inhibitors. In this context, it is important to identify as early as possible patients highly likely to respond. This study aims at identifying, among axial spondyloarthritis patients undergoing treatment with the TNF inhibitor adalimumab, early molecular biomarkers differentiating good responders from non-responders after 14 weeks of treatment, as measured by ASAS20.

44 Methods: Peripheral blood RNA sequencing and serum proteins measured by mass 45 spectrometry were evaluated in a cohort of biologic naïve axial spondyloarthritis patients (n = 46 35), before (baseline) and after (3-5 days, 2 weeks and 14 weeks) treatment with adalimumab. 47 Results from differential expression analysis were used in combination with clinical data to build 48 logistic regression models and random forest models to predict response to adalimumab at 49 baseline.

50 **Results:** Responders to adalimumab presented higher levels of markers of innate immunity at 51 baseline, mostly related with neutrophils, and lower levels of adaptive immunity markers, 52 particularly B-cells. A logistic regression model incorporating ASDAS-CRP and AFF3, the top 53 differentially expressed gene between responders and non-responders at baseline, enabled an 54 accurate prediction of response to adalimumab in our cohort (AUC=0.96), with random forest 55 models suggesting 80% predictive accuracy. A treatment-associated signature suggests a 56 reduction in inflammatory activity, with C-reactive protein and Haptoglobin showing strong and 57 early decrease in the serum of axial spondyloarthritis patients, while a cluster of apolipoproteins 58 showed increased expression at week 14.

59 **Conclusions**: Differences in disease activity and/or blood innate/adaptive immune cell type 60 composition at baseline may be a major contributor to response to adalimumab in axial 61 spondyloarthritis, where a model including clinical and blood gene expression variables shows 62 high predictive power. Our results suggest novel molecular biomarkers of response to 63 adalimumab at baseline.

Trial registration: Axial spondyloarthritis patients were selected from participants of the
 Bioefficacy study - Biomarkers Identification of Anti-TNFα Agent's Efficacy in Ankylosing

Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry (clinical trials.gov
 identifier NCT02492217).

Keywords: Axial spondyloarthritis, TNF inhibitor, Adalimumab, Treatment response, Disease
activity, Innate immune system, Adaptive immune system, Peripheral blood, RNA sequencing,
Proteomics.

71

#### 72 BACKGROUND

73 Axial Spondyloarthritis (axSpA) can lead to significant disability and impairment in guality of life 74 [1]. Inflammatory back pain is a characteristic symptom, and new bone formation with 75 syndesmophytes and ankylosis are the disease radiographic hallmarks. Clinical features of 76 axSpA are heterogeneous, including inflammatory back pain, asymmetrical peripheral 77 oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such 78 as acute anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Pulmonary, renal, 79 neurological, aortic root involvement and conduction abnormalities are all rare complications of 80 axSpA [2].

81 In axSpA, non-steroidal anti-inflammatory drugs (NSAIDs) have a central role in treatment and 82 are considered the first-choice drug treatment. However, biological disease-modifying 83 antirheumatic drugs (bDMARDs) including TNF inhibitors (TNFi), are recommended to patients 84 enduring active disease despite conventional treatment (or intolerance/contraindication) [3]. The 85 efficacy of TNFi has been documented in several studies showing significant and early 86 improvements in disease activity and function [4] sustainable for long periods of time [5]. In spite 87 of its well documented benefit in axSpA, up to an estimated 40% axSpA patients fail to respond 88 to TNFi treatment [6] or complain with adverse events [7].

The concept of "window of opportunity" is of critical importance in rheumatoid arthritis (RA) [8] and seems to be also relevant in the axSpa context, with studies of magnetic resonance

91 imaging in the context of TNFi treatment suggesting that early effective suppression of 92 inflammation has the potential to reduce radiographic damage [9]. Patients that fail to respond 93 to the first bDMARD usually switch to another bDMARD (with the same or other mechanism of 94 action, such as IL-17 inhibitors [10]), and it may take several iterations to find a drug that 95 reduces disease activity [3]. Response to an effective therapy can take several weeks/months, 96 and the delay caused by non-response may imply irreversible damage. In this context, it is 97 important to identify as early as possible the patients highly likely to respond, meaning to 98 achieve remission or low disease activity, following the treat to target concept [11].

99 Studies specifically in axSpA indicate that primary non-responders to TNFi tend to be older, 100 HLA-B27 negative, with longer disease duration (> 20 years), higher structural damage and 101 poor function [12]. Likewise, good response to therapy was associated with younger age, HLA-102 B27 carriage, short disease duration (<10 years), elevation of acute phase reactants (CRP), and 103 marked spinal inflammation (detectable by MRI) [13]. Higher levels of CRP is the most common 104 marker associated with good response, but higher levels of other inflammation markers such as 105 IL6 [14] and calprotectin [15] have also been associated with positive outcomes of TNFi 106 treatment.

107 The molecular characterization of anti-TNF response in axSpA revealed the unsurprising 108 involvement of genes related with immunity and inflammation [16,17]. Although several studies 109 address the overall effect of TNFi treatment in the axSpA context [18], very few specifically 110 address the molecular changes associated with response/non-response to anti-TNF treatment 111 in axSpA, most of them focusing on specific markers of inflammation in the sera of a limited set 112 of patients. In particular, no study systematically assessed large scale transcriptomics and/or 113 proteomics data to find early predictors of response to anti-TNF in axSpA. On the other hand, 114 several studies have tried to develop such predictors in RA, with variable success [19-21]. One 115 study using whole blood transcriptomics achieved 65% accuracy of response to infliximab in RA

with a 10-gene biomarker set [19]. In another study using transcriptomics of monocytes, CD11c
was found to be a very good predictor of response (95% accuracy) to adalimumab monotherapy
in RA [20]. Thomson and colleagues used publicly available data to develop a model including
18 signaling mechanisms that could increase the capacity to discover non-responders, from
27% to 59% [21]. More recently, several studies suggested an interplay between innate and
adaptive immunity, with a higher myeloid-driven inflammation in responders and higher
lymphoid activity in non-responders [21–23].

Reliable predictors of outcome for anti-TNF monotherapies in axSpA are currently not yet available. The goal of this study is thus the identification of baseline predictors, using transcriptomic and proteomic approaches, of patient response to anti-TNF therapy (adalimumab) in axSpA using peripheral blood samples, which are particularly appealing given the relative ease of obtaining samples as part of patient follow-up.

128

#### 129 METHODS

#### 130 Study design and samples collection

131 AxSpa patients were selected from participants of the Bioefficacy study - Biomarkers 132 Identification of Anti-TNFa Agent's Efficacy in Ankylosing Spondylitis Patients Using a 133 Transcriptome Analysis and Mass Spectrometry (clinical trials.gov identifier NCT02492217). 134 This is a multicentric, prospective, nonrandomized, 14-weeks study that includes axSpA adult 135 patients according to axSpA ASAS criteria [24]. The study included biologic naïve patients, 136 starting TNFi therapy with adalimumab (40mg subcutaneously fortnightly), according to the 137 Portuguese Society of Rheumatology Guidelines [25] (see supplementary material). Clinical 138 evaluations and peripheral blood collections were performed at baseline (start bDMARD), and

139 after 3-5 days, 2 weeks and 14 weeks. Patients were classified as responders and non-140 responders, according to ASAS20 [26,27] at week 14. To have 80% power to detect a 0.5SD 141 difference between groups at p=0.05 (paired t-test), we estimated that we would need samples 142 from 18 responders and 18 non-responders. Usually only 60% of patients after starting TNFi reach ASAS20, which means that we would need to include a larger number of patients to 143 144 establish the subgroups for analysis. Thus, we included the number of patients necessary to 145 ensure 18 non-responders, after which we closed the recruitment period. All clinical evaluations 146 were performed by previously trained rheumatologists. Blood samples were collected from all 147 subjects at baseline to test for HLA-B27 status and at each timepoint to determine C-reactive 148 protein (CRP), Erythrocyte Sedimentation Rate (ESR), other biochemical parameters and for 149 RNA-seq and serum proteomic analysis.

#### 150 RNA preparation and NGS sequencing (RNA-seq)

151 Peripheral blood samples were collected into PAXgene Blood RNA System® tubes and stored 152 at -80° C according to the manufacturer's recommendations [28]. Total RNA was extracted from 153 whole blood samples according to the standard PAXgene protocol (Qiagen, 2008). The quantity 154 of RNA was measured using a NanoDrop 2000/2000c Spectrophotometer according to the 155 manufacturer's procedure (Thermo-Scientific, 2000); RNAs with a 260:280 ratio of ≥1.5 were 156 sequenced as below. The quality and quantity of the libraries was assessed by Fragment 157 Analyzer with the method of DNF-474-22 - HS NGS Fragment 1-6000bp (Agilent). Sequencing 158 library preparation was performed using Illumina TruSeq stranded mRNA library preparation 159 kits, with 100ng of total RNA as input. Libraries were sequenced on an Illumina NextSeg500 160 sequencer (average of 39 million reads per sample, 75 base-pair paired-end). Sample 161 correspondence between timepoints was confirmed using SmaSH [29]. We also used the 162 transcriptomic data to confirm gender and HLA-B27 status.

### 163 RNA-Seq data analysis

164 Raw sequencing reads were aligned to gencode (v32) transcripts using kallisto (version 0.46.1) 165 [43], reaching an average of 86% reads assigned to genes (gene counts are in Supp. Table 11). 166 The edgeR R package was used to filter low-expressed genes with the filterBvExpr function and 167 to normalize raw counts with the trimmed mean of M-values (TMM) normalization approach [44]. 168 The limma R package was used to apply a voom transformation for variance stabilization [45], 169 and to obtain differentially expressed genes through an empirical bayes approach. Genes were 170 considered differentially expressed if the adjusted p-value of the test was less than 0.05. 171 Functional enrichment analysis was performed using the fasea R package, based on ranks of 172 the moderated t-statistic from the empirical bayes analysis. The per-gene variance explained by 173 each variable was estimated using the variancePartition R package. Permutational multivariate 174 analysis of variance (adonis) was performed using the vegan R package.

#### 175 Inference of Immune cell populations from RNA-Seq data

176 The hemograms collected in each timepoint were used to correlate with data obtained from 177 transcriptomic analysis. As common hemograms did not provide specific information on B-cells 178 and other more specific cell types, we used Cibersort [30] to infer relative frequencies of 179 immune cell populations by comparing normalized log2(counts per million) of the blood 180 transcriptomes to the Abbas et al. signatures [31]. To assess the accuracy of these 181 measurements, we correlated the relative frequencies obtained with RNA-Seq with the values 182 we obtained with clinical hemograms (Supplemental Figure 8A,B, pearson R=0.84 and p=3.3e-8 for Neutrophils, R=0.86 and p=1.2e-8 for Lymphocytes). For consistency, we used only 183 184 frequencies from Cibersort estimated values in the analyses for Fig4C and Fig2D, and in logistic 185 regression models. In Supp. Fig. 8C,D we used exclusively hemogram data, and in Supp. Fig. 186 8E.F we used frequencies estimated with Cibersort confirming the same conclusions.

187 Quantitative set analysis for gene expression (QUSAGE) [32] was used to assess the fold
188 change of immune signature gene sets from Lewis et al. [33] (Supp. Fig. 7A).

#### 189 Proteomics Analysis (LC-MS/MS)

190 Immunoaffinity depletion of high-abundance proteins. Peripheral blood samples were 191 collected into Clot Activator Tubes (Monovette Serum Gel Z- 7.5 mL, Sarsted) containing 100 µL 192 of Protease Inhibitor Cocktail (Sigma-Aldrich). The six most abundant proteins in serum were 193 depleted using the Multiple Affinity Removal Spin Cartridge Human 6 Kit (Agilent 194 following manufacturer's instructions. The remaining proteins were Technologies®) 195 concentrated using 4 mL Spin Concentrators with 5000 MWCO (Agilent Technologies®). A 196 centrifugation was performed (with a fixed angle rotor) at 4000 x g and 10°C until the sample 197 reached a volume between 100 and 140 µL, after which it was recovered from the bottom of the 198 concentrator pocket and stored at -20°C until further analysis. In order to quantify the amount of 199 protein in each sample, the QuantiPro<sup>™</sup> BCA Kit (Sigma-Aldrich®) was used.

200 **In-gel protein digestion.** 50 µg of total proteins was diluted with MilliQ water to a final volume of 201 20 µL and 10 µL of LDS3X (Invitrogen<sup>™</sup> by Life Technologies<sup>™</sup>) was added, for a final volume 202 of 30 µL. Samples were heated for 5 min at 99°C and briefly centrifuged (16,000 g for 1 min). 203 The whole volume of the supernatant containing the soluble proteins was loaded on a NuPAGE 204 4-12% Bis-Tris (Invitrogen<sup>™</sup> by Life Technologies<sup>™</sup>) gel and the proteins were subjected to 205 SDS-PAGE electrophoresis for 5 min. After migration, the gels were stained with Coomassie 206 SimplyBlue SafeStain (Invitrogen<sup>™</sup> by Life Technologies<sup>™</sup>) for 5 min and washed with water 207 overnight with gentle agitation. Polyacrylamide bands containing the stained proteome were cut 208 by the limit of gel wells, between the front of migration and the well bottom. Each sample was 209 treated and proteolyzed with trypsin Gold (Promega©) in presence of ProteaseMax detergent 210 (Promega©) as previously described [46]. The final volume of peptide extract was 50 µL.

211 LC-MS/MS analysis. Tryptic peptides were analyzed with a Q-Exactive<sup>™</sup> HF high resolution 212 tandem mass spectrometer (ThermoFisher Scientific<sup>™</sup>) incorporating an ultra-high-field Orbitrap 213 analyser as previously described [34]. Shortly, 10 µL of the resulting peptide mixtures for each 214 sample were injected in a random order. First, peptides were desalted online on a reverse 215 phase precolumn Acclaim PepMap 100 C18 (5 µm, 100 Å, 300 µm id x 5 mm), and then, they 216 were resolved on a reverse phase column Acclaim PepMap 100 C18 (3 µm, 100 Å, 75 µm id x 217 500 mm) at a flow rate of 200 nL/min with a 90 min gradient of 4 to 25 % of B in 75 min and 25 218 to 40% of B in 15 min (being A: 0.1% HCOOH and B: 80% CH3CN, 0.1% HCOOH). The Q-219 Exactive HF instrument was operated according to a Top20 data-dependent method consisting 220 in a scan cycle initiated with a full scan of peptide ions in the ultra-high-field Orbitrap analyzer, 221 followed by serial selection of each of the 20 most abundant precursor ions, high energy 222 collisional dissociation and MS/MS scans. Full scan mass spectra were acquired from m/z 350 to 1,500 with a resolution of 60,000. A peptide exclusion list was established for the most 223 224 abundant immunodepleted proteins: serum albumin (https://www.uniprot.org/uniprot/P02768) 225 complement C3 (P01024), alpha-2-macroglobulin (P01023), and apolipoprotein B-100 226 (P04114), in order to focus the analysis on the other proteins. Each MS/MS scan was acquired 227 with a threshold intensity of 83.000, on potential charge states of 2+ and 3+ after ion selection 228 performed with a dynamic exclusion of 10 sec, maximum Inclusion Time (IT) of 60 ms and an 229 m/z isolation window of 2.0. MS/MS spectra at a resolution of 15.000 were searched using 230 MASCOT 2.5.1 software (Matrix Science) against the Swissprot Human database downloaded 231 in July 2019 (20.432 Homo sapiens protein sequences). The following parameters were used 232 for MS/MS spectra assignation: full trypsin specificity, maximum of two missed cleavages, mass 233 tolerances of 5 ppm on the parent ion and 0.02 Da on the secondary ions, fixed modification of 234 carbamidomethyl cysteine (+57.0215), and oxidized methionine (+15.9949) and deamidated 235 (NQ) (0.9840) as dynamic modifications.

236 Protein identification and relative quantification. After LC-MS/MS, a bioinformatic analysis 237 was performed where all peptide matches with a MASCOT peptide score below a query identity 238 threshold p-value of 0.05 were filtered and assigned to proteins. A total of 5.453.298 MS/MS 239 spectra were recorded and 1.632.427 spectra were assigned to peptide sequences from the 240 protein database - these peptide spectral matches are listed in Supp. Table 12. A protein 241 identification was considered valid when at least two different non-ambiguous peptides were 242 detected in the whole dataset. False discovery rate (FDR) for proteins was below 1% when 243 applying these rules with the MASCOT decoy search mode. A total of 333 polypeptide 244 sequences were identified based on at least 2 non-ambiguous peptides - from the initially 377 245 polypeptide sequences identified, 44 contaminant proteins (keratin and keratin associated 246 proteins) were excluded from further analysis. For each validated protein (listed in Supp. Table 247 12), the number of MS/MS spectra for all detected non-ambiguous peptides or 'Spectral Count' (SC) [47] was used as a proxy of their abundances [48]. To further assess the value of SC as a 248 249 measure of protein abundance, we compared clinically determined CRP levels with CRP levels 250 measured by proteomics, and found these to be highly correlated (Supp. Fig. 9, pearson 251 R=0.73, spearman rho=0.79, p<2e-16). Differential protein analysis was performed similarly to 252 the transcriptomics, using the SC values as counts.

253

#### 254 Data analysis

Descriptive statistics were used to summarize baseline characteristics for responders and nonresponders. Two sample Wilcoxon tests (continuous variables) and chi-square tests of association (categorical variables) were used to compare characteristics between responders and non-responders at different timepoints, in particular between baseline and week 14.

Differential gene and protein expression analysis used the limma R package to apply a voom transformation for variance stabilization on normalized expression values, and to obtain differentially expressed genes through an empirical bayes approach, followed by multiple test correction with the Benjamini-Hochberg method. Genes were considered differentially expressed if the adjusted *p*-value of the test was less than 0.05.

- Logistic regression models, and plotting was performed using the R software. Sparse partial least squares discriminant analysis (sPLS-DA) was performed using the mixOmics R package. Random forest models were obtained using the randomForest R package.
- 267

268 RESULTS

# The TNF inhibitor adalimumab induced a reduction in disease activity of most axSpa patients

271 According to the ASAS20 criteria we obtained 18 non-responders, and selected, from the whole 272 cohort, 18 responders matched to non-responders by age and gender (one non-responder was 273 later excluded as it had missing information). Table 1 briefly summarizes the clinical 274 characteristics of this sub-group of 35 patients included in this study. Responders presented higher values of C-reactive protein (CRP) (p=0.011) and ASDAS-CRP (p<0.001) at baseline 275 276 (BL). Responders had a higher proportion of HLA-B27 (p=0.01), with 83% having the allele 277 against only 41% of non-responders. Disease activity decreased from baseline to week 14 278 (w14) in both responders (ASDAS-CRP: from 4.2 at baseline to 1.6 at week 14, p=2e-04; 279 BASDAI: from 6.5 to 1.9, p=2e-04) and non-responders (ASDAS-CRP: from 3.2 to 2.5, p=5e-04; 280 BASDAI: from 5.3 to 4.0, p=6e-03) (Table 1, Supp. Fig. 1A,B). This suggests that treatment with

TNFi, with a few exceptions, has lowered inflammatory markers and disease activity scores inmost patients.

#### 283 Treatment with adalimumab had a significant impact on the expression of blood cell

transcripts and serum proteins of axSpa patients.

285 Expression levels of blood cell transcripts and abundances of serum proteins in axSpA patients 286 did not clearly separate responders from non-responders in an unsupervised principal 287 component analysis (PCA) at neither BL nor at w14 (Fig. 1A). Nonetheless, serum proteomics 288 showed clear differences between BL and w14 in responders, suggesting an effective impact of 289 adalimumab treatment. Indeed, a sparse partial least squares discriminant analysis (sPLS-DA) 290 supports a separation between BL and W14, for both responders and non-responders, not only 291 in proteomics (Supp. Fig. 2), but also in transcriptomics (p<0.05, Fig. 1B). Permutational 292 multivariate analysis of variance indicates that both time points (3% and 17%) and response 293 groups (2% and 4%) can explain a small but statistically significant (p<0.05) part of the 294 observed global variation both in transcript and protein levels, respectively. Moreover, sPLS-DA 295 analysis supports a separation between responders and non-responders at baseline (p<0.01, 296 Fig. 1C). This suggests that treatment with TNFi had a significant impact in the expression of 297 blood cell transcripts and serum proteins of axSpA patients undergoing treatment with 298 adalimumab. Moreover, it also suggests the existence of detectable differences between 299 responders and non-responders at baseline.

# Blood transcriptome data at baseline suggests that response to adalimumab derived from an interplay between innate and adaptive immunity.

We tested for differences in gene expression or protein abundance between responders and non-responders at baseline. No proteins (of 112) were found to be significantly differentially abundant between the two groups at BL (Supp. Table 9), but we could detect 92 (of 18688)

305 genes (12 with FC>2) differentially expressed between responders and non-responders at BL. with 16 (0 with FC>2) more expressed in responders and 76 (12 with FC>2) more expressed in 306 307 non-responders (Fig. 2A, Supp. Table 10). Genes more expressed in responders are associated 308 with inflammation, such as neutrophil degranulation and interferon signaling, while genes more 309 expressed in non-responders are associated with lymphocyte activation, namely B-cell activity, 310 and metabolism, namely translation (Fig. 2B). The top differentially expressed genes are PAX5, 311 MS4A1 (CD20), FCRLA, BANK1 and AFF3, all associated with B-cells and all significantly more 312 expressed in non-responders at BL (Fig. 2C). Corroborating this observation, estimation of 313 lymphocyte population frequencies using RNA-Seq indicates significantly higher frequencies of 314 B-cells in non-responders at BL (Fig. 2D). Genes associated with B-cells show the strongest 315 overall difference between responders and non-responders at BL. Moreover, there is a 316 significant positive correlation between disease activity and estimated neutrophil frequencies, 317 and a negative correlation between disease activity and estimated B- and T- cell frequencies at 318 BL (Supp. Fig. 7B). Thus, our results suggest that response to adalimumab derives from 319 alterations in the balance between innate and adaptive immunity, indicating an opposing role 320 particularly between neutrophils and B-cells.

# 321 Blood transcriptome data improved ability to differentiate responders versus non-322 responders at baseline

In our cohort, ASDAS-CRP at baseline was significantly (p=0.011) associated with response in a multivariate logistic model of association with TNFi response (Fig. 3A). HLA-B27 status was also significant (p=0.034), while age at diagnosis and disease duration did not reach statistical significance. ASDAS-CRP was more elevated in responders, with an optimal threshold of 4.15 (100% sensitivity and 50% specificity) when considered in isolation (area under the curve (AUC) = 0.83, Fig. 5B). A model incorporating simultaneously the clinical parameters ASDAS-CRP and HLA-B27 reached an AUC of 0.88. Interestingly, a model replacing HLA-B27 with the ratio

330 between neutrophils and total lymphocytes (N/L) achieved an AUC of 0.84, hinting at the potential for the use of hemogram data as a simple alternative to predict response to treatment. 331 332 Finally, we incorporated in our models variables from the transcriptomic data. For this, we chose 333 the most robustly differentially expressed gene between responders and non-responders at 334 baseline, which was AFF3, a tissue-restricted nuclear transcriptional activator preferentially 335 expressed in lymphoid tissues. This gene presented the lowest false discovery rate (0.006), and 336 a fold change of 1.9 (higher in non-responders, Fig. 2A,B). Adding the gene expression values 337 of AFF3 to a logistic regression model including ASDAS-CRP increased the AUC to 0.96 (Fig. 338 3B). If we choose the second most robust differentially expressed gene (BANK1), we reach a 339 similar AUC of 0.94 (not shown). Moreover, a random forest model using ASDAS-CRP, and 340 AFF3 achieved a predictive accuracy of 80%, better than using ASDAS-CRP alone (60%) or 341 only clinical variables ASDAS-CRP and HLA-B27 (70%). Thus, our results suggest that blood 342 transcriptome data can improve our ability to differentiate responders from non-responders at 343 baseline, and that simple hemogram data can have valuable clinical application.

# 344 Transcripts and proteins varying between baseline and week 14 were associated with a

#### 345 decrease in innate immune activity

To assess more concretely the impact of adalimumab treatment, we first looked for differences in gene expression and protein abundance between BL and w14. In responders, 2120 (of 21438) genes (103 genes with fold change (FC) greater than 2) and 41 (of 129) proteins (7 with FC>2) were differentially abundant between BL and w14, of which 1096 genes (41 with FC>2) and 25 proteins (4 with FC>2) were upregulated at w14 (Fig. 4A, Supp. Tables 1,2).

In responders, genes associated with inflammation, particularly neutrophil-driven (such as *DOK3*, *LRG1*, and *MMP9*), tended to be significantly less expressed in blood cells at w14 in comparison to BL, while upregulated genes were associated mostly with translation and other

354 metabolic processes (eg. EEF1A1, RPL7, MRPL1, Fig. 4B). In agreement with this, serum proteins less abundant at w14 were associated with the activation of the complement system 355 356 and innate immunity, including the complement factors CFB and CFH, and complement 357 components C3, C8B and C8G (Fig. 4B, Supp. Table 2). Serum proteins more abundant at w14 358 were linked with vitamin metabolism, including the apolipoproteins APOA1, APOA2, and 359 APOA4. Given the consistent decrease in expression of Neutrophil and innate immunity 360 markers, we also compared estimated frequencies of different white blood cells between BL and 361 w14. In agreement with the gene expression results, we observe in responders a significant 362 decrease in neutrophil frequency at week 14, and an increase of B cell frequency (Fig. 4C), with 363 a similar pattern observed for other adaptive immune cell populations such as CD4+ T-cells 364 (Supp. Fig. 7A).

365 In non-responders, no significant differences in blood cell gene expression were found between 366 BL and w14 (Supp. Fig. 3 and Supp. Table 3). Nonetheless, a rank-based gene set enrichment 367 analysis (GSEA) of the transcriptomics data uncovers the same pathways as in responders 368 (Supp. Fig. 4). In non-responders, 16 serum proteins were found differentially expressed (none 369 with FC>2), of which 11 upregulated at w14, including APOA1, CLEC3B, CFH and RBP4 (Supp. 370 Table 4). No significant pathways are found in the proteomics data. Also, although there is a 371 similar tendency to decrease neutrophil frequency between BL and w14 in non-responders, it 372 does not reach statistical significance in neutrophils nor other immune cell populations (Supp. 373 Fig. 7A).

Genes and proteins differentially abundant between BL and w14 in responders were at more similar levels between the two patient groups at w14 (p<0.05), suggesting preexisting differences at baseline that got attenuated due to treatment (Supp. Fig. 5). In agreement with this observation, we did not find any genes or proteins displaying significantly different behavior between time and response group, suggesting that the action of adalimumab in responders and

379 non-responders is similar. Overall, these results suggest that transcripts and proteins varying
380 during adalimumab treatment were associated with a decrease in innate immune activity.

381

# 382 Markers of inflammation were already lowered in the serum after 3-5 days of adalimumab 383 treatment, in both responders and non-responders.

384 To refine our understanding of the temporal response to adalimumab, we performed serum 385 proteomics analysis also at 3-5 days and 2 weeks after beginning of treatment. In responders, 386 among the serum proteins significantly downregulated at w14 in comparison to BL, Haptoglobin 387 (HP), Haptoglobin receptor (HPR) and CRP showed a tendency to decrease already at 3-5 388 days, further decreasing until 2 weeks (Fig. 5A, Supp. Tables 5.6). These proteins also tended 389 to decrease in non-responders, particularly in the first two weeks (Supp. Fig. 6A-C, Supp. 390 Tables 7.8). Another group of proteins (including CFH and CFB) displayed a mild continuous 391 decrease through time, while genes like C3 and C8A only appeared to decrease noticeably 392 between week 2 and week 14. Among the proteins significantly increasing in w14 in comparison 393 with BL in responders, there was greater heterogeneity, but some, including APOD, APOA2 and 394 PPBP displayed a tendency to increase their abundance already at week 2, including in non-395 responders (Fig. 5B, Supp. Fig. 6D). Interestingly, the average level of change of these proteins 396 was much milder (maximum FC of 2) when compared to HP, HPR and CRP (FC of 3-5). Thus, 397 our results indicate that some markers of inflammation elevated at baseline were already 398 lowered in the serum of some patients after just 3-5 days of adalimumab treatment.

399

400 **DISCUSSION** 

This work documented that adalimumab treatment has a significant effect in transcript expression and protein abundances during the first 14 weeks of treatment. In our axSpA cohort, TNFi treatment seems to lower inflammatory markers in most patients, as observed in previous studies [4] and suggests an interplay between innate and adaptive immunity. Lymphoid markers such as *AFF3*, and Neutrophil/Lymphocyte ratios, emerge as novel differentiating variables between groups and enable highly accurate predictive models.

407 The main objective of our study was to identify molecular predictors, at BL, of response to TNFi. 408 Our results corroborate ASDAS-CRP as an effective measure to decide, as promptly as 409 possible, about TNFi as a therapeutic option in axSpA. However, the cut-off to predict response 410 to therapy at baseline with maximum sensitivity is 4.1, representing a very high disease activity. 411 Therefore, more variables are necessary for an accurate prediction, particularly in cases of 412 moderate disease activity. Adding HLA-B27 status brought further improvements, while the 413 addition of other variables (age at disease onset, disease duration) didn't seem to add further 414 resolution to the model. The observation of an interplay between innate and adaptive immunity. 415 also reported in previous studies in RA [23], suggest similar mechanisms in both diseases. Our 416 analysis suggests that the ratios between innate/adaptive immune populations, such as 417 neutrophils/lymphocyte ratios deserve further exploration as a simple clinical marker with 418 interest regarding TNFi therapeutic decision. In agreement with this, replacing HLA-B27 with the 419 ratio of neutrophil frequencies over total lymphocytes at BL enabled an accurate model, 420 although it didn't seem to improve over HLA-B27. This suggests a potential clinical interest, 421 particularly when HLA-B27 status is not easily available.

422 At the transcriptional level, our analysis revealed significant differences in several genes related 423 to B cells (*AFF3*, *CD19*, *MS4A1*, *FCRLA*, *BANK1*, *PAX5*). In fact, the most enriched pathways 424 were associated with B-cell development and activation (genes less expressed in responders), 425 and to a lesser extent, neutrophil and inflammatory activity (eg. *RIPK3*, genes more expressed

426 in responders). At the proteomic level, we could not detect any protein consistently different at 427 baseline between responders and non-responders. One possible reason may be that B cell 428 proteins are present at too low a level in serum, which combined with the overall heterogeneity 429 of the samples, made these undetectable in our proteomic analysis. We then used RNA-Seq 430 data to estimate frequencies of different white blood cell populations that are not provided in the 431 normal clinical hemogram, such as B-Cells. Our analysis confirmed a higher frequency of 432 neutrophils, and a lower relative frequency of B cells (and of other adaptive immune 433 populations) in responders in comparison with non-responders at baseline. Adding AFF3, a B-434 cell associated gene that was the top differentially expressed gene at BL between responders 435 and non-responders, in a logistic regression model with ASDAS-CRP, enabled a very accurate 436 prediction of response to adalimumab (AUC=0.96). A similarly high predictive capacity was 437 obtained with another B-cell associated gene (BANK1) providing further consistency to our 438 results. Moreover, using the same models with robust machine learning methods including 439 cross-validation suggests a predictive capacity of over 80% accuracy, an estimate which is likely 440 to be very conservative given the small size of our cohort.

441 To provide further insights regarding the molecular mechanisms involved in the differential 442 response to TNFi treatment, we obtained measures of expression for blood transcripts and 443 serum proteins of axSpA patients during 14 weeks of treatment with adalimumab. Our 444 transcriptomics and proteomics data indicate that a significant fraction of the observed variation 445 in gene expression can be explained by treatment time and response status. Moreover, 446 transcripts and proteins with significantly reduced expression between BL and w14 of treatment 447 were associated with inflammation and innate immunity, in agreement with the observed 448 changes in clinical markers of inflammation and scores of disease activity. Taken together, this 449 suggests the existence of clinically relevant information in the data and the potential to uncover 450 early biomarkers of TNFi response.

451 Our transcriptomic results are in large agreement with previous results in axSpA. Namely, 452 TNFSF14 (LIGHT), IL17RA, and EPOR, genes reported by Haroon et al. [16], also had 453 significantly reduced expression after TNFi treatment in our cohort (the gene IFNAR1 didn't 454 reach significance in our study but had a borderline adjusted p-value of 0.07). Moreover, 58 (16%) of 360 genes upregulated after TNFi in Wang et al. [17] were also upregulated in our 455 456 study, and 88 (31%) of 285 down regulated genes were also detected in our study (with only 457 one gene showing opposing significant tendencies between the studies). Among the 103 458 significantly differentially expressed genes (DEGs) between BL and w14 with higher fold 459 changes (FC>2), ten had been previously identified as axSpA-associated in GWAS [35]. Of 460 these, TNFRSF1A, TBKBP1, HHAT, and LTBR, all less expressed at w14, are involved in the 461 TNF pathway, mediate apoptosis through nuclear factor- $\kappa B$ , and function as a regulator of 462 inflammation [36]. Interestingly, IL1R, IL6R and TYK2, more associated with innate immunity, 463 were downregulated, while IL7R and ICOSLG, more associated with the adaptive immune 464 system, namely the stimulation and differentiation of T and B cells, were upregulated. FCGR2A, 465 also downregulated, encodes a cell surface receptor found on phagocytic cells, such as, 466 macrophages and neutrophils. This indicates that, despite heterogeneity in clinical 467 manifestations of axSpA, molecular response to TNFi seems consistent between different 468 studies, at least at the level of the blood cell transcriptome. These results suggest that 469 biomarkers of TNFi response uncovered in our cohort are likely to be generally applicable in the 470 axSpA context, although further validation is still mandatory.

Our study expands on previous works in the axSpA context by introducing proteomics data, including intermediate timepoints during adalimumab treatment. We identified several serum proteins undergoing significant changes in abundance with adalimumab treatment. Overall, we observe a decrease in the abundances of HP, HPR, CRP and complement factors, and an increase of several apolipoproteins, CLEC3b and RBP4. Interestingly, in responders, an early

476 (since days 3-5) and persistent decrease of HP and CRP is seen, correlating with observed clinical improvement. Decrease of complement factors is milder and occurs later (after week 2). 477 478 A later increase of apolipoproteins APOA1, APOA2 and APOD, involved in lipid clearance from 479 circulation and anti-inflammatory properties, has been previously shown [37]. Curiously, APOD 480 has no marked similarity to other apolipoprotein sequences, but has a high degree of homology 481 to plasma retinol-binding protein (Rbp), which is also overexpressed, and both are thought to 482 influence bone metabolism [37,38]. Rbp4 seems to be present in a restricted population of 483 epiphyseal chondrocytes and perichondrial cells correlating to the future regions of secondary 484 ossification. In addition, CLEC3B, a plasminogen-binding protein induced during the 485 mineralization phase of osteogenesis, is also more abundant [39]. These data unravel molecular 486 mechanisms underlying the abrogation of inflammation, while also suggesting that 487 osteoproliferation may be induced under TNFi therapy, as documented in recent studies [40-488 42]. Future studies should aim to uncover the physiopathological role of these genes in TNFi 489 response.

We acknowledge limitations in our study, namely the need for further validation with targeted approaches and in new cohorts. Moreover, as all patients were under adalimumab treatment, we cannot extrapolate the results to other TNFi, although comparison with analysis in RA suggest that the underlying mechanisms will be similar.

#### 494 CONCLUSIONS

To our knowledge, this study is the first using a multi-omic approach to tackle the difficult challenge of predicting at BL the therapeutic response to TNFi in the axSpA context. Our results suggest an interplay between innate and adaptive immunity occurring under TNFi therapy, with lymphoid markers emerging as the most differentially expressed between groups and enabling highly accurate predictive models with our cohort. In addition, our work confirms transcriptomics results of previous studies investigating the effects of TNFi in axSpA and expands them by

- 501 providing a genome-wide census of both blood cell genes expression and serum proteins 502 abundances during the first 14 weeks of treatment with Adalimumab, in both responders and
- 503 non-responders.
- 504 Taken together, our results suggest that molecular data can not only provide mechanistic
- 505 insights to the genesis and progression of the disease, but also suggest novel biomarkers to
- 506 evaluate the potential response to adalimumab before initiating treatment or in its initial phases.

## 507 **DECLARATIONS**

### 508 Ethics approval and consent to participate:

509 This study (registered in clinical trials.gov with the identifier NCT02492217) was approved by 510 the national competent authorities: National Ethics Committee for Clinical Research (CEIC) and INFARMED (competent authority to regulate medicinal products). The study was conducted 511 512 according to Good Clinical Practices (GCP), Declaration of Helsinki, and legal regulation 513 applicable, ensuring participants' safety and mechanisms for data protection. Written informed 514 consent was obtained from all participants before study inclusion. None of the patient identifiers 515 were known to anyone outside of the research group. There was no active involvement of 516 patients or the public as co-producers of research in this project. However, all participants were 517 invited to participate in a meeting where the main results were presented and discussed.

## 518 Availability of data and materials

519 Transcriptomics and proteomics data are available as supplementary tables in zenodo under 520 the DOI https://doi.org/10.5281/zenodo.4914646. Mass spectrometry data are available through PRIDE 521 the ProteomeXchange Consortium via the partner repository identifiers 522 (https://www.ebi.ac.uk/pride/), PXD026189 under dataset and 523 http://doi.org/10.6019/PXD026189.

## 524 **Competing Interests**:

525 F.M.P.-S. has received research grants by Abbvie, Janssen, Novartis, and received consulting 526 fees from AbbVie, Astra Zeneca, Biogen, Celgene, Eli-Lilly, Janssen, Novartis, Pfizer, 527 Tecnimed, UCB, J.L.-G, received consulting fees from Abbvie, Pfizer, H.S. received consulting 528 fees from Abbvie, Eli-Lilly, Novartis, Pfizer. J.T.-C. received consulting fees from AbbVie, 529 AMGEN, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, UCB. M.B. received consulting fees from 530 Lilly, Janssen and Abbvie. For all authors with potential conflicts of interest, these were not 531 directly related to this study. The other authors declare that there are no conflicts of interest to 532 disclose.

### 533 Funding

534 D.S. was funded by a fellowship from Fundação para a Ciência e Tecnologia (PTDC/MED-535 ONC/28660/2017). This study was funded by Abbvie but the funder had no influence in study 536 design, data analysis and writing of the submitted document.

# 537 Author's Contributions:

538 Study concept and design: F.M.P.-S., J.C.B.; Acquisition of clinical data: M.B., P.P., H.S., J.L.-

539 G., J.T.-C., J.A.P.S., J.M.D., A.B., S.M., J.C.B., F.M.P.-S.; Laboratorial research direction:

540 A.V.C., F.M.P.-S.; Performance of laboratory experiments: A.S., A.F.F., F.M.P.-S., A.V.C., J.-

541 C.G., J.A., V.B.; Analysis and interpretation of data: D.S., A.V.C., A.F.F., F.M.P.-S.; Writing of

542 the manuscript: D.S., A.V.C., A.F.F., F.M.P.-S.; Critical revision of the manuscript for important 543 intellectual content: All authors.

# 544 Acknowledgments

545 We thank the members of the computational multi-omics group for critical reading of the 546 document. We acknowledge the careful comments provided by 2 anonymous reviewers in a 547 previous submission.

- 549 Abbreviations
- 550 **ASAS:** assessment in ankylosing spondylitis
- 551 ASDAS: ankylosing spondylitis disease activity score
- 552 AUC: area under the curve
- 553 **axSpA:** axial spondyloarthritis
- 554 **BASDAI:** bath ankylosing spondylitis disease activity index
- 555 **bDMARD:** biological disease-modifying antirheumatic drugs
- 556 BL: baseline
- 557 **ESR:** erythrocyte sedimentation rate
- 558 FC: fold change
- 559 **GSEA:** gene set enrichment analysis
- 560 **HLA-B27:** human leukocyte antigen B27
- 561 **MRI:** magnetic resonance imaging

- 562 **NSAID:** non-steroidal anti-inflammatory drugs
- 563 **PCA:** principal component analysis
- 564 **RA:** rheumatoid arthritis
- 565 **sPLS-DA:** sparse partial least squares discriminant analysis
- 566 **TNFi:** tumor necrosis factor inhibitor
- 567 **w14:** week 14
- 568

### 569 **REFERENCES**

- 570 1 Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 571 spondyloarthritis: Curr Opin Rheumatol 2010;22:375–80.
- 572 doi:10.1097/BOR.0b013e32833ac5cc
- 573 2 CORPOREA Study Group, Pimentel-Santos FM, Mourão AF, et al. Spectrum of ankylosing
   574 spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference
   575 centile charts, Clin Rheumatol 2012;31:447–54, doi:10.1007/s10067-011-1854-7
- 576 3 van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR
  577 management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
  578 doi:10.1136/annrheumdis-2016-210770
- 579 4 Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing
   580 spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis
   581 2015;74:1241–8. doi:10.1136/annrheumdis-2014-205322
- 582 5 Zochling J, Braun J. Management and treatment of ankylosing spondylitis: Curr Opin 583 Rheumatol 2005;17:418–25. doi:10.1097/01.bor.0000163194.48723.64
- Alazmi M, Sari I, Krishnan B, et al. Profiling Response to Tumor Necrosis Factor Inhibitor
  Treatment in Axial Spondyloarthritis. Arthritis Care Res 2018;70:1393–9.
  doi:10.1002/acr.23465
- 587 7 Chen K, Wei X-Z, Zhu X-D, et al. Whole-blood gene expression profiling in ankylosing
  588 spondylitis identifies novel candidate genes that may contribute to the inflammatory and
  589 tissue-destructive disease aspects. Cell Immunol 2013;286:59–64.
  590 doi:10.1016/j.cellimm.2013.10.009
- Nell VPK. Benefit of very early referral and very early therapy with disease-modifying anti rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906–14.
   doi:10.1093/rheumatology/keh199
- Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial
   spondyloarthritis. Arthritis Res Ther 2014;16:109. doi:10.1186/ar4561
- 596 10 Blair HA. Secukinumab: A Review in Ankylosing Spondylitis. Drugs 2019;79:433–43.
   597 doi:10.1007/s40265-019-01075-3
- 598 11 Dougados M. Treat to target in axial spondyloarthritis: From its concept to its 599 implementation. J Autoimmun 2020;110:102398. doi:10.1016/j.jaut.2019.102398
- Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to
   anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis
   2007;67:1276–81. doi:10.1136/ard.2007.073098
- Rudwaleit M. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor
   blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665–70.

### 605 doi:10.1136/ard.2003.016386

- Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment
  responses and their relation to biomarkers of inflammation, cartilage and bone turnover in
  patients with axial spondyloarthritis treated with TNF inhibitors. Ann Rheum Dis
  2011;70:1375–81. doi:10.1136/ard.2010.138883
- Turina MC, Yeremenko N, Paramarta JE, et al. Calprotectin (S100A8/9) as serum biomarker
  for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis.
  Arthritis Res Ther 2014;16:413. doi:10.1186/s13075-014-0413-4
- 613 16 Haroon N, Tsui FWL, O'Shea FD, et al. From gene expression to serum proteins: biomarker
  614 discovery in ankylosing spondylitis. Ann Rheum Dis 2010;69:297–300.
  615 doi:10.1136/ard.2008.102277
- Wang XB, Ellis JJ, Pennisi DJ, et al. Transcriptome analysis of ankylosing spondylitis
   patients before and after TNF-α inhibitor therapy reveals the pathways affected. Genes
   Immun 2017;18:184–90. doi:10.1038/gene.2017.19
- Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloarthritis and Related
   Diseases, Impact on the Immune System and Prediction of Treatment Responses. Front
   Immunol 2019;10:382. doi:10.3389/fimmu.2019.00382
- Tanino M, Matoba R, Nakamura S, et al. Prediction of efficacy of anti-TNF biologic agent,
  infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of
  white blood cells. Biochem Biophys Res Commun 2009;387:261–5.
  doi:10.1016/j.bbrc.2009.06.149
- Stuhlmüller B, Häupl T, Hernandez MM, et al. CD11c as a Transcriptional Biomarker to
   Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid
   Arthritis. Clin Pharmacol Ther 2010;87:311–21. doi:10.1038/clpt.2009.244
- Thomson TM, Lescarbeau RM, Drubin DA, et al. Blood-based identification of nonresponders to anti-TNF therapy in rheumatoid arthritis. BMC Med Genomics 2015;8:26.
  doi:10.1186/s12920-015-0100-6
- 632 22 Oswald M, Curran ME, Lamberth SL, et al. Modular Analysis of Peripheral Blood Gene
  633 Expression in Rheumatoid Arthritis Captures Reproducible Gene Expression Changes in
  634 Tumor Necrosis Factor Responders. Arthritis Rheumatol 2015;67:344–51.
  635 doi:10.1002/art.38947
- Farutin V, Prod'homme T, McConnell K, et al. Molecular profiling of rheumatoid arthritis
  patients reveals an association between innate and adaptive cell populations and response
  to anti-tumor necrosis factor. Arthritis Res Ther 2019;21:216. doi:10.1186/s13075-0191999-3
- Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of
  SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part
  II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
  doi:10.1136/ard.2009.108233
- 644 25 Machado P, Cerqueira M, Ávila-Ribeiro P, et al. Portuguese recommendations for the use of
  645 biological therapies in patients with axial spondyloarthritis 2016 update. Acta Reumatol
  646 Port 2017;42:209–18.
- Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group
  preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum
  2001;44:1876–86. doi:10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F
- Brandt J. Development and preselection of criteria for short term improvement after antiTNF treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438–44.
  doi:10.1136/ard.2003.016717
- Kruhøffer M, Dyrskjøt L, Voss T, et al. Isolation of Microarray-Grade Total RNA, MicroRNA,
  and DNA from a Single PAXgene Blood RNA Tube. J Mol Diagn 2007;9:452–8.
  doi:10.2252/imoldy.2007.060175

- Westphal M, Frankhouser D, Sonzone C, et al. SMaSH: Sample matching using SNPs in
   humans. BMC Genomics 2019;20:1001. doi:10.1186/s12864-019-6332-7
- 658 30 Chen B, Khodadoust MS, Liu CL, et al. Profiling Tumor Infiltrating Immune Cells with
  659 CIBERSORT. In: von Stechow L, ed. Cancer Systems Biology. New York, NY: : Springer
  660 New York 2018. 243–59. doi:10.1007/978-1-4939-7493-1\_12
- 661 31 Abbas AR, Wolslegel K, Seshasayee D, et al. Deconvolution of Blood Microarray Data
  662 Identifies Cellular Activation Patterns in Systemic Lupus Erythematosus. PLoS ONE
  663 2009;4:e6098. doi:10.1371/journal.pone.0006098
- 32 Yaari G, Bolen CR, Thakar J, et al. Quantitative set analysis for gene expression: a method
   to quantify gene set differential expression including gene-gene correlations. Nucleic Acids
   Res 2013;41:e170. doi:10.1093/nar/gkt660
- 33 Lewis MJ, Barnes MR, Blighe K, et al. Molecular Portraits of Early Rheumatoid Arthritis
  Identify Clinical and Treatment Response Phenotypes. Cell Rep 2019;28:2455-2470.e5.
  doi:10.1016/j.celrep.2019.07.091
- Klein G, Mathé C, Biola-Clier M, et al. RNA-binding proteins are a major target of silica
  nanoparticles in cell extracts. Nanotoxicology 2016;10:1555–64.
  doi:10.1080/17435390.2016.1244299
- 673 35 The Australo-Anglo-American Spondyloarthritis Consortium (TASC). Genome-wide
  674 association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet
  675 2010;42:123–7. doi:10.1038/ng.513
- 36 Hacker H, Karin M. Regulation and Function of IKK and IKK-Related Kinases. Sci STKE
   2006;2006:re13–re13. doi:10.1126/stke.3572006re13
- White CR, Garber DW, Anantharamaiah GM. Anti-inflammatory and cholesterol-reducing
  properties of apolipoprotein mimetics: a review. J Lipid Res 2014;55:2007–21.
  doi:10.1194/jlr.R051367
- Martineau C, Najyb O, Signor C, et al. Apolipoprotein D deficiency is associated to high
  bone turnover, low bone mass and impaired osteoblastic function in aged female mice.
  Metabolism 2016;65:1247–58. doi:10.1016/j.metabol.2016.05.007
- Wewer UM, Ibaraki K, Schjørring P, et al. A potential role for tetranectin in mineralization
   during osteogenesis. J Cell Biol 1994;127:1767–75. doi:10.1083/jcb.127.6.1767
- Bruijnen STG, Verweij NJF, van Duivenvoorde LM, et al. Bone formation in ankylosing
  spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron
  emission tomography. Rheumatology 2018;57:631–8. doi:10.1093/rheumatology/kex448
- 689 41 Gulyás K, Horváth Á, Végh E, et al. Effects of 1-year anti-TNF-α therapies on bone mineral
  690 density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin
  691 Rheumatol 2020;39:167–75. doi:10.1007/s10067-019-04771-3
- Boers N, Michielsens CAJ, van der Heijde D, et al. The effect of tumour necrosis factor
  inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature
  review. Rheumatology 2019;58:1907–22. doi:10.1093/rheumatology/kez363
- 695 43 Bray NL, Pimentel H, Melsted P, et al. Near-optimal probabilistic RNA-seq quantification.
  696 Nat Biotechnol 2016;34:525–7. doi:10.1038/nbt.3519
- 44 Robinson MD, Oshlack A. A scaling normalization method for differential expression
   analysis of RNA-seq data. Genome Biol 2010;11:R25. doi:10.1186/gb-2010-11-3-r25
- 699 45 Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA700 sequencing and microarray studies. Nucleic Acids Res 2015;43:e47–e47.
  701 doi:10.1093/nar/gkv007
- 46 Hartmann EM, Allain F, Gaillard J-C, et al. Taking the shortcut for high-throughput shotgun
  proteomic analysis of bacteria. Methods Mol Biol Clifton NJ 2014;1197:275–85.
  doi:10.1007/978-1-4939-1261-2\_16
- Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by
   multidimensional protein identification technology. Nat Biotechnol 2001;19:242–7.

- 707 doi:10.1038/85686
- 48 Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative
  protein abundance in shotgun proteomics. Anal Chem 2004;76:4193–201.
  doi:10.1021/ac0498563
- 711 Figure Legends

712 Figure 1: Response to TNFi has a significant impact on the relative abundance of blood 713 cells transcripts and serum proteins of patients. A) Principal Component Analysis (PCA) of 714 the blood cell transcriptomics and proteomics data for responders (R) and non-responders (NL) 715 at baseline (BL) and week 14 (W14). For visual clarity two outliers are out of view in the 716 transcriptomics PCA, but all data was used to generate the plot; B) Sparse partial least squares 717 discriminant analysis (sPLS-DA) of transcriptomics data, using time as a variable of interest, in 718 responders (AUC=0.99, permutation test p=8e-07) and non-responders (AUC=1, p=6.4e-07); C) 719 sPLS-DA of transcriptomics (AUC=1, p=9.6e-07) and proteomics (AUC=1, p=3.4e-05) data at 720 baseline, using response group as a variable of interest. In all cases, AUC and p-value 721 correspond to the two best components of the sPLS-DA. In all graphs, ellipses represent 95% 722 confidence intervals.

723 Figure 2: Blood transcriptome data at baseline suggests response to adalimumab 724 derives from an interplay between innate and adaptive immunity. A) Volcano plot (log2 of 725 the fold change versus -log10 of the false discovery rate (FDR)) comparing the transcriptomics 726 responder versus non-responder samples at baseline (Supp. Table 10); B) Barplot displaying 727 the Normalized Enrichment Score (NES) of representative significant pathways resulting from a 728 gene set enrichment analysis (GSEA) comparing the gene expression of responder versus non-729 responder samples at baseline; C) Heatmap representation of the expression profile of the top 730 40 differentially expressed genes comparing responder versus non-responder samples at 731 baseline; for visualization purposes, expression values of each gene were scaled towards a 732 standard distribution (z-score); rows and columns were clustered by correlation; D) Estimated B-733 cell and Neutrophil frequencies in responder and non-responder samples at baseline:


734 Figure 3: Blood transcriptome data improves ability to differentiate responders versus 735 non-responders at baseline. A) Forest plot displaying the logarithm of the odds, 95% 736 confidence interval and p-value of response to adalimumab for different variables from a logistic 737 regression model. B) Receiver operating characteristic (ROC) curve displaying specificity and 738 sensitivity for different logistic regression models incorporating: only ASDAS-CRP scores (Area 739 Under the Curve - AUC=0.83); ASDAS-CRP scores and HLA-B27 status (AUC=0.88); ASDAS-740 CRP scores and the ratio between the estimated frequency of neutrophils and total lymphocytes 741 (N/L, AUC=0.84); ASDAS-CRP and the normalized expression value of AFF3 (AUC=0.96).

Figure 4: Transcripts and proteins varying between baseline and week 14 were associated with a decrease in innate immune activity. A) Volcano plot (log2 of the fold change versus -log10 of the false discovery rate (FDR)) comparing the blood cell transcriptomics (Supp. Table 1) and serum proteomics (Supp. Table 2) baseline samples versus week 14 samples in responders; non-significant (NS) genes/proteins are in grey; in green genes/proteins that are not statistically significant (FDR>0.05) but have an estimated fold

748 change greater than 2; in blue genes/proteins that are statistically significant but have a milder 749 fold change (less than 2); in red genes/proteins that are statistically significant and have a fold 750 change greater than 2. All red proteins and some of the red gene names are displayed in the 751 plot. B) Barplot displaying the Normalized Enrichment Score (NES) of representative significant 752 pathways resulting from a gene set enrichment analysis (GSEA) comparing the gene 753 expression or protein abundances of w14 (green) against BL (blue) responder samples; C) 754 Boxplot displaying estimated Neutrophil or naive B-cell frequencies in BL and w14 samples. In 755 C the p-value is from a paired Wilcoxon rank-sum test; Samples of the same patient are 756 connected with a grey line.


Figure 5: Markers of inflammation are already lowered in the serum after 3-5 days of adalimumab treatment, in both responders and non-responders. A) Log2 fold change of proteins between a given time point and the baseline. Only proteins significantly downregulated at w14 in responders were represented. B) Same as A but with upregulated proteins. We clustered proteins with similar temporal behavior using the dtwclust R package. Only the names of a set of representative proteins are displayed.


763 Table 1. Summary of the clinical characteristics of the cohort. For each continuous variable, 764 the mean and standard deviation within each group were calculated. Two sample Wilcoxon tests (continuous variables) and chi-square tests of association (categorical variables) were 765 766 used to compare characteristics between "Responders" and "Non-Responders". Variables 767 include Erythrocyte Sedimentation Rate (ESR, in mm / h), C-Reactive Protein (CRP, in mg / L), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, Bath Ankylosing 768 769 Spondylitis Functional Index (BASFI) scores, Ankylosing Spondylitis Disease Activity Score (ASDAS) using the ESR levels (ASDAS-ESR) or CRP levels (ASDAS-CRP). For these 770 771 characteristics, the value at baseline and week 14 is provided, as well as the difference between 772 the two endpoints. Other fixed clinical characteristics include age at diagnosis (in years of age), 773 disease duration (in years since start of first symptoms), presence (Positive) or absence 774 (Negative) of the HLA-B27 allele, and sex (biological gender) – Female or Male.






Transcriptomics: Baseline versus Week 14






С


Responders versus Non-Responders at Baseline








Α

medRxiv preprint doi: https://doi.org/10.1101/2022.08.02.22278314; this veGon posted August 3, 2022. The copyright holder for this preprint Responder with the second with the second with the second medRxiv a license to display the preprint in perpetuity. Transcriptories It is made available under a CC-BY-NC-ND 4.0 International license for the second seco











Α




#### Figure 4


#### Α **Baseline versus Week 14 in Responders Baseline versus Week 14 in Responders** Trans (Which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.








**Baseline versus Week 14 in Responders** Proteomics




Normalized Enrichment Score (NES)


С



Responders: pval = 0.0092




A medRxiv preprint doi: https://doi.org/10.1101/2022.08.02.22278314; this version posted August 3, 2022. The copyright holder for this preprint (which was newpotal eddytors of down gullated plasmapheteins) has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



в

Temporal evolution of upregulated plasma proteins



#### Table 1

medRxiv preprint doi: https://doi.org/10.1101/2022.08.02.22278314; this version posted August 3, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It's made available under a CC-BY-NC-ND 4.0 International license . Mean (sd) Mean (sd) p value

				P
Erythrocyte (mm/h)	Sedimentation Rate			
(((((((((((((((((((((((((((((((((((((((	Baseline	26.059 (20.355)	33.167 (28.461)	0.541
	Week 14	11.882 (10.741)	10.833 (9.102)	0.856
	BL - W14	14.176 (16.253)	22.333 (23.450)	0.298
C-Reactive (mg / L)	Protein			
(IIIg / L)	Baseline	11.312 (11.507)	23.692 (19.678)	0.011
	Week 14	7.418 (10.882)	3.896 (2.776)	0.754
	BL - W14	3.894 (4.781)	19.796 (19.375)	< 0.001
BASDAIsco	ore			
	Baseline	5.347 (2.629)	6.528 (1.463)	0.234
	Week 14	4.065 (2.181)	1.928 (1.443)	0.003
	BL - W14	1.282 (1.502)	4.600 (1.814)	< 0.001
BASFIscon	e			
	Baseline	5.291 (2.717)	6.709 (1.906)	0.156
	Week 14	3.712 (2.653)	2.548 (2.097)	0.176
	BL - W14	1.578 (1.490)	4.161 (2.064)	< 0.001
ASDAS-ESF	R score			
	Baseline	3.229 (0.861)	3.761 (1.083)	0.203
	Week 14	2.271 (0.929)	1.478 (0.498)	0.008
	BL - W14	0.959 (0.566)	2.283 (1.004)	< 0.001
ASDAS-CRI	P score			
	Baseline	3.159 (0.748)	4.156 (0.756)	< 0.001
	Week 14	2.459 (0.753)	1.561 (0.572)	< 0.001
	BL - W14	0.700 (0.507)	2.594 (0.940)	< 0.001
Age at Diag (years)	nosis			
() ()		37.862 (11.279)	34.851 (11.635)	0.301
Disease dur (years)	ration			
		14.822 (12.742)	13.718 (7.494)	0.869
HLA-B27 Status				0.010
	Negative	10 (58.8%)	3 (16.7%)	
	Positive	7 (41.2%)	15 (83.3%)	
Gender				0.915
	Female	5 (29.4%)	5 (27.8%)	
	Male	12 (70.6%)	13 (72.2%)	